The Technical Analyst
Oragenics Inc [OGEN]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
Oragenics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
33.33% $1.840
America/New_York / 10 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.24 mill |
| EPS: | -4.60 |
| P/E: | -0.400 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 4.48 mill |
| Avg Daily Volume: | 0.101 mill |
| RATING 2024-05-10 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.400 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.400 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.246 (-32.30%) $-0.594 |
| Date: 2024-05-12 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.698 - 1.982 ( +/- 7.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-31 | Koski Robert C | Buy | 0 | |
| 2023-12-28 | Redmond J Michael | Buy | 75 000 | Employee Option (Right to Buy) |
| 2023-12-28 | Redmond J Michael | Buy | 0 | |
| 2023-11-30 | Telling Fred | Sell | 3 500 | Common Stock |
| 2023-10-04 | Gandolfo John P | Buy | 5 102 | Non-Employee Director Option (Right to Buy) |
| INSIDER POWER |
|---|
| 41.83 |
| Last 90 transactions |
| Buy: 9 608 650 | Sell: 19 845 876 |
Forecast:
16:00 - $1.840
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.840
Forecast 2: 16:00 - $1.840
Forecast 3: 16:00 - $1.840
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.840 (33.33% ) |
| Volume | 0.441 mill |
| Avg. Vol. | 0.101 mill |
| % of Avg. Vol | 436.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OGEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OGEN
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Last 10 Buy Signals
Latest Press Releases
2024-04-19 17:50:00 - Press Release
Oragenics, Inc. Announces Notification Of Noncompliance With Additional Nyse American Continued Listing Standards
Sarasota, fla.--(business wire)--oragenics, inc. (nyse american: ogen), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “notice”) from the nyse american llc (the “nyse american”) dated april 18, 2024, notifying the company that it is no longer in compliance with nyse american continued listing standards. specifically, the letter states that the company is not in compliance with the con.
2024-03-18 07:00:00 - Press Release
Oragenics Appoints James Kelly Md, Chief Medical Officer, To Lead Phase Ii Clinical Trials For Treating Concussion
Sarasota, fla.--(business wire)--oragenics, inc. (nyse american: ogen), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed dr. james “jim” kelly, neurologist, as its chief medical officer, to oversee its upcoming phase ii clinical trial. oragenics' lead drug candidate, onp-002 is combined with its intranasal device intended for the treatment of mild traumatic brain injury (tbi), aka concussion. onp-002.
2024-03-05 07:45:00 - Press Release
Oragenics, Inc. Prepares Drug For Phase Ii Clinical Trials To Treat Concussion
Sarasota, fla.--(business wire)--oragenics, inc. (nyse american: ogen), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of gmp manufacturing and formulation of its drug candidate for its expected phase iia clinical trial. the drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild traumatic brain injury, aka concussion. oragen.
2024-03-01 16:04:00 - Press Release
Oragenics Announces Closing Of Public Offering
Sarasota, fla.--(business wire)--oragenics, inc. (nyse american: ogen) (“oragenics” or the “company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses.
2024-02-27 21:25:00 - Press Release
Oragenics Announces Pricing Of Public Offering
Sarasota, fla.--(business wire)--oragenics, inc. (nyse american: ogen) (“oragenics” or the “company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the company.
Latest News
2024-02-28 08:29:37 - InvestorPlace
Why Is Oragenics (OGEN) Stock Down 45% Today?
Oragenics (NYSEMKT: OGEN ) stock is falling on Wednesday after the antibiotics development company announced details of a public offering for its shares. Oragenics is selling 1.4 million shares of OGEN stock for $1.50 each.
2023-01-30 14:24:37 - InvestorPlace
7 Short-Squeeze Stocks to Buy Before They Soar
As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, market bears operate like great white sharks.
2022-12-26 14:20:11 - PennyStocks
Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch
Penny stocks to buy under $1: A Beginner's Guide The post Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-07 16:46:12 - InvestorPlace
5 Stocks Insiders Are Buying Right Now
Several stocks that insiders are buying are worth watching as we enter the new year. This week, that list includes F, CRCT, CHWY and OGEN.
2022-01-06 15:52:52 - PennyStocks
4 Top Penny Stocks To Buy Right Now According To Insiders
Insiders decided to buy these penny stocks recently The post 4 Top Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-04 13:34:24 - PennyStocks
3 Penny Stocks To Watch Under $1 That Are Moving Right Now
Looking for penny stocks to buy under $1? Check these three out for your watchlist The post 3 Penny Stocks To Watch Under $1 That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-04 12:02:28 - InvestorPlace
OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph Today
Oragenics (OGEN) stock is rising higher on Tuesday following news of massive insider buying at the development-stage company. The post OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph Today appeared first on InvestorPlace.
2022-01-04 06:32:33 - Pulse2
Oragenics Stock (OGEN): Why The Price Surged Today
The stock price of Oragenics Inc (NYSEAMERICAN: OGEN) increased by over 20% pre-market today. This is why it happened.
2021-12-21 07:12:48 - Pulse2
Oragenics Stock (OGEN): Why The Price Increased
The stock price of Oragenics Inc (NYSEAMERICAN: OGEN) increased by 7.27% in the previous trading session. This is why it happened.
2021-12-20 12:08:12 - Benzinga
Oragenics Extends Collaboration with NRC Canada For Omicron-Specific Vaccine
Oragenics Inc (NYSE: OGEN) has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) to enable Oragenics to pursue an intranasal vaccine designed against omicron variant. The NRC cell expression technologies provide Oragenics with a platform to generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern.